---
figid: PMC12249569__ijms-26-06537-g001
figtitle: Mechanistic model linking gut dysbiosis, insulin resistance, and autism
  spectrum disorder
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC12249569
filename: ijms-26-06537-g001.jpg
figlink: /pmc/articles/PMC12249569/figure/F1/
number: F1
caption: Mechanistic model linking gut dysbiosis, insulin resistance, and autism spectrum
  disorder. Gut dysbiosis leads to increased intestinal permeability, allowing lipopolysaccharides
  to enter the bloodstream. This triggers the activation of TLR4 and TLR2/1 through
  MyD88. Consequently, this initiates the TRAF6–MAPK–NF-κB signaling pathway, resulting
  in an elevation in pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β, and IL-18.
  These cytokines induce inhibitory phosphorylation of IRS1, which dampens the PI3K/AKT-GLUT4
  pathway and contributes to systemic insulin resistance. The resulting chronic inflammation
  and disruption of the blood–brain barrier promote neuroinflammation and neurodevelopmental
  changes associated with ASD
papertitle: Mechanistic Links Between Gut Dysbiosis, Insulin Resistance, and Autism
  Spectrum Disorder
reftext: Patricia Guevara-Ramírez, et al. Int J Mol Sci. 2025 Jul;26(13).
year: '2025'
doi: 10.3390/ijms26136537
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: healthcare | autism spectrum disorder | microbiota | insulin resistance
  | molecular pathways
automl_pathway: 0.9152801
figid_alias: PMC12249569__F1
figtype: Figure
redirect_from: /figures/PMC12249569__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12249569__ijms-26-06537-g001.html
  '@type': Dataset
  description: Mechanistic model linking gut dysbiosis, insulin resistance, and autism
    spectrum disorder. Gut dysbiosis leads to increased intestinal permeability, allowing
    lipopolysaccharides to enter the bloodstream. This triggers the activation of
    TLR4 and TLR2/1 through MyD88. Consequently, this initiates the TRAF6–MAPK–NF-κB
    signaling pathway, resulting in an elevation in pro-inflammatory cytokines, such
    as TNF-α, IL-6, IL-1β, and IL-18. These cytokines induce inhibitory phosphorylation
    of IRS1, which dampens the PI3K/AKT-GLUT4 pathway and contributes to systemic
    insulin resistance. The resulting chronic inflammation and disruption of the blood–brain
    barrier promote neuroinflammation and neurodevelopmental changes associated with
    ASD
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IRF6
  - TLR2
  - TLR1
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - MYD88
  - IRS1
  - SLC2A4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - AKT1
  - AKT2
  - AKT3
  - TRAF6
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NFKB1
  - TNF
  - IL6
  - IL18
  - tlr2
  - tlr1
  - myd88
  - irs1
  - traf6
  - tnfrsfa
  - tnfb
  - il6
  - Insulin
  - LPS
  - Glucose
---
